From the tightening 2025 enforcement landscape to named-patient prescribing, the rules governing how a practitioner orders a prescription-only medicine have changed materially.
For any UK aesthetic practitioner who sources medicines from a pharmacy, the compliance obligations around prescription-only medicines (POMs) are detailed and non-negotiable. Whether you are a nurse prescriber running an independent clinic or a dentist working from a multi-practitioner setting, your ability to order POMs lawfully depends on a clearly documented chain: a valid prescription, a verified prescriber identity, a registered pharmacy operating within its licence, and a patient record that supports every supply made.
This guide explains each link in that chain, covering the named-patient prescription model, how a GPhC-registered pharmacy verifies credentials before releasing stock, what changed under the September 2025 enforcement, and how practitioner registration at a compliant aesthetics pharmacy works in practice.
What a POM Is and Why Ordering Is Controlled
A prescription-only medicine is defined under the Human Medicines Regulations 2012 as a medicinal product that may only be sold or supplied in accordance with a prescription given by an appropriate practitioner. The classification covers a broad range of products used routinely in aesthetic practice, including botulinum toxin type A, hyaluronidase, certain local anaesthetics, topical and systemic antibiotics, and a number of other injectable agents.
The rationale for POM control is patient safety. These medicines carry risks that require clinical assessment before use. Botulinum toxin type A, for example, can cause distant spread of toxin effect; hyaluronidase carries an allergy risk that demands a considered clinical decision before administration. Ordering any POM without a valid prescription, or from a source that does not hold the appropriate licence, is a criminal offence under the Human Medicines Regulations 2012 and may also constitute a fitness-to-practise concern with the relevant professional regulator.
The Named-Patient Prescription Model
In aesthetic practice, the overwhelmingly common prescribing model for injectable POMs is the named-patient prescription. Under this model, a prescription is written by an authorised prescriber for a specific, identifiable patient following an appropriate clinical consultation. The prescription names the patient, the medicine, the dose, the route of administration, and the quantity to be supplied.
This contrasts with a stock or wholesale supply model, which is governed by a separate licensing framework and is not appropriate for standard clinic use. Named-patient prescriptions must meet the legal requirements set out in regulation 217 of the Human Medicines Regulations 2012. They must be signed in ink (or via an approved electronic prescribing system) by the prescriber, dated, and include the prescriber's name, address, and professional registration number.
A pharmacy dispensing against a named-patient prescription is obliged to check the prescription is genuine, current, and has not already been dispensed. It is also obliged to check that the prescriber is registered and authorised to prescribe the medicine in question. These are not discretionary checks; they are legal obligations on the pharmacy as dispenser.
Prescriber vs Non-Prescriber Practitioners
A central distinction that determines how a practitioner may access POMs is whether they hold an independent prescribing qualification.
Independent prescribers include doctors (GMC registered), dentists (GDC registered), and nurses or pharmacists who hold a recorded independent prescribing annotation on their NMC or GPhC registration respectively. An independent prescriber may assess a patient and write a prescription for a POM within their competence, without referring to another prescriber.
Non-prescriber practitioners, including many aesthetic nurses, beauty therapists, and paramedical practitioners without a prescribing annotation, cannot legally write a POM prescription. They must work under a patient group direction (PGD), a patient-specific direction (PSD) written by a prescribing colleague, or via a prescriber-led model where a prescriber carries out the clinical consultation and authorises supply before the practitioner administers.
The Joint Council for Cosmetic Practitioners (JCCP) register is one recognised source for verifying the registration status and scope of practitioners working in the aesthetics sector. A GPhC-registered pharmacy will look to registration bodies and qualification records to confirm that the person ordering or receiving a POM is authorised to do so.
What a GPhC-Registered Pharmacy Must Verify Before Supply
A pharmacy registered with the General Pharmaceutical Council (GPhC) operates under professional standards that require it to take reasonable steps to assure itself that a supply is lawful and clinically appropriate before releasing a POM.
For a new account request, this typically involves the following checks carried out before any order is fulfilled:
- Verification of the prescriber's registration number with the relevant regulatory body (GMC, GDC, NMC, or GPhC).
- Confirmation that the registration is current, has no conditions that restrict prescribing, and is not subject to interim orders.
- Review of the qualifications or training records supporting the practitioner's scope of practice in aesthetics.
- Confirmation that valid professional indemnity insurance is in place and covers the intended treatments.
- Review of the clinic or business address and, where applicable, its registration with the Care Quality Commission (CQC) or the relevant devolved equivalent.
- Confirmation of the prescribing model in use at the clinic, particularly whether the practitioner is an independent prescriber or is working under a prescriber-led arrangement.
These checks are not a one-time exercise. A compliant pharmacy will re-verify registration status at the point of each order cycle and will require updated documentation when indemnity policies renew or when a practitioner changes their prescribing arrangement.
Credential and Identity Checks in Detail
Practitioner verification at an aesthetics pharmacy covers three categories of documentation.
Registration body confirmation. The pharmacy will check the relevant public register directly. For doctors, this is the GMC's online medical register. For nurses with an independent prescribing annotation, the NMC register shows the prescribing qualification clearly. For dentists, the GDC register confirms scope. This check is not satisfied by the practitioner simply asserting their registration number; the pharmacy must confirm the record independently.
Indemnity insurance. A valid policy must be in force at the date of supply and must cover the specific treatments or medicines for which the practitioner is ordering. Some policies exclude certain injectables or require endorsement for specific procedures. The pharmacy may request the schedule or certificate of insurance, not just a declaration.
Qualifications and scope of practice. For aesthetic POMs, the pharmacy will want evidence that the practitioner has completed recognised training for the procedures in which the medicine will be used. This is particularly relevant for botulinum toxin type A and hyaluronidase, where misuse carries a material patient-safety risk. Recognised training providers and registers such as the JCCP provide a reference point, though the pharmacy makes its own assessment.
The September 2025 Enforcement and What Changed
In September 2025, the MHRA, GPhC, and the Advertising Standards Authority (ASA) took coordinated action to address the widespread advertising of POMs directly to consumers in the aesthetics and weight-management sectors. The enforcement focused on online advertising, social media promotion, and websites that named specific prescription medicines, described their effects, or created demand for them without going through a prescriber consultation.
The joint position, as set out in the GPhC and MHRA joint advertising guidance and the ASA announcement of its partnership with the MHRA and GPhC, clarified that:
- Naming a specific POM in advertising directed at or accessible by the public constitutes unlawful promotion of a prescription medicine under regulation 285 of the Human Medicines Regulations 2012.
- This applies regardless of whether the advertisement includes a disclaimer or a request to consult a prescriber.
- Pharmacy websites, clinic websites, and social media accounts are all in scope.
- Pharmacies that were found to be advertising POMs in breach of these rules faced regulatory action, including fitness-to-practise proceedings against the responsible pharmacist.
For practitioners, the practical implication is that the pharmacies still operating in the aesthetics sector post-enforcement are, by definition, the ones that have aligned their processes with the regulatory framework. Working with a GPhC-registered pharmacy that holds the appropriate MHRA Wholesale Dealer Authorisation (Human) provides a documented basis for compliant supply.
How Practitioner Registration and Approval Works at Longeva Pharmacy
Longeva Pharmacy operates as a GPhC-registered pharmacy (registration 9012378) under MHRA WDA(H) licence 59619. Practitioner accounts are subject to a structured verification process before any POM order is processed.
The registration process, which can be initiated via the practitioner registration page, requires the following to be submitted and verified before account approval:
- Full name and professional registration number with the relevant body (GMC, GDC, NMC, GPhC, or equivalent).
- Confirmation of prescribing status, including the prescribing annotation where applicable.
- Current professional indemnity certificate.
- Evidence of aesthetic training or qualifications relevant to the products being ordered.
- Clinic name, registered address, and CQC registration number where required.
Accounts are reviewed by the pharmacy team. New account applications are not automatically approved. Once approved, practitioners can browse and order from the full product range. If you have queries at any stage of the process or need to discuss a specific prescribing arrangement, the pharmacy team can be contacted via the contact page.
Account information is held in accordance with UK GDPR and is used solely for the purposes of order processing, verification, and regulatory record-keeping.
Record Keeping and Traceability
Both the prescriber and the pharmacy are required to maintain records that support a complete audit trail for every POM supplied. The legal minimum for pharmacy records of POM supply is set out in the Human Medicines Regulations 2012 and GPhC standards for registered pharmacies.
For practitioners, the corresponding obligation is to retain prescription records, patient consultation notes, batch numbers of medicines administered, and adverse event documentation. These records must be available for inspection by the relevant regulatory body and, in the context of clinical negligence or regulatory investigation, will be central to demonstrating that supply and administration were lawful.
Batch number traceability is particularly important in aesthetics because it supports product recall notifications. If a batch of botulinum toxin type A or any other POM is recalled by the manufacturer or MHRA, the pharmacy and the practitioner must each be able to identify whether they hold or have administered product from that batch, and to act accordingly.
Practitioners should ensure their clinic systems record the following for every POM administration: patient name and date of birth, date of treatment, product name and strength, batch number and expiry date, volume or dose administered, prescriber name and registration number, and the practitioner who administered.
Yellow Card Reporting
The MHRA's Yellow Card scheme is the UK system for reporting suspected adverse reactions to medicines, including POMs used in aesthetics. Reporting is a professional obligation, not optional. The scheme collects data that informs MHRA decisions on product safety, labelling, and, in some cases, continued authorisation.
Reportable events in aesthetic practice include unexpected reactions at the injection site, systemic effects, complications that required medical intervention, and any event that the practitioner considers might be related to the medicine administered. Near-misses and events involving off-label use are also within scope.
Reports can be submitted directly by the practitioner via the Yellow Card website or app. The pharmacy may also file a report if the adverse event is brought to its attention. Both reports are not duplicative in regulatory terms; each provides a different perspective on the event.
Key Takeaways
- A POM may only be supplied against a valid, signed prescription from an authorised prescriber for a named patient.
- Non-prescriber practitioners must work within a lawful prescribing arrangement such as a PSD or PGD; they cannot self-prescribe or order independently.
- A GPhC-registered pharmacy is legally obliged to verify prescriber registration, indemnity, and scope of practice before opening an account or processing a POM order.
- The September 2025 enforcement by the MHRA, GPhC, and ASA clarified that naming a POM in any advertising accessible to consumers is unlawful, regardless of disclaimers.
- Practitioners must maintain full records of every POM administered, including batch numbers, to support traceability and respond to recall notifications.
- Suspected adverse reactions to any POM must be reported via the MHRA Yellow Card scheme.
- Working with a pharmacy that holds both GPhC registration and an MHRA WDA(H) licence provides the documented supply chain a compliant practitioner needs.